Market Trends of Uterine Cancer Therapeutics & Diagnostics Industry
This section covers the major market trends shaping the Uterine Cancer Therapeutics & Diagnostics Market according to our research experts:
Endometrial Adenocarcinoma to Witness Highest Growth Over the Forecast Period
Growing burden of endometrial adenocarcinoma is expected to drive the Uterine Cancer Therapeutics & Diagnostics Market in this segment. According to the Cancer.gov, an endometrial adenosarcoma is the most common type of cancer which is found in women and about 80 percent of uterine cancers are adenocarcinomas, and vary in degree of severity.
Increasing obesity among women is considered as the prime factor responsible for the growing incidence of the endometrium carcinoma as around 90% of the uterine cancers affect the endometrium. with the growing incidence of the disease and the rising awareness about the same, it is believed that rapid growth of the segment will occur in the coming future.
North America is Expected to Dominate the Market over the Forecast Period
North America region is believed to dominate the Global Uterine Cancer Therapeutics and Diagnostics Market in the near future. The prime reason for the growth of the market in this region is the rising incidence of the disease and the growing awareness among the general population. American Cancer Society estimates that in 2020, around 65,620 new cases of uterine body cancer in the United States. Furthermore, around 10% of uterine body cancers are sarcoma. In addition, rapid technological advancements in the diagnostics and faster adoption to new technologies in the country are provoking the overall growth of the market studied.